CSL Behring, a global biotherapeutics leader has received FDA) approval for its supplemental request (submitted Aug. 30, 2020) for co-packaging of a convenience administration kit along with its product Berinert, indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients.
Deciphera Pharmaceuticals, Inc. announced that Nature Medicine has published results from a circulating tumor DNA (ctDNA) analysis of the INTRIGUE Phase III study of Qinlock (ripretinib) in GIST patients with mutations in KIT exon 11 and 17/18 only previously treated with imatinib.
Delcath Systems announced it submitted a new drug application (NDA) resubmission to the FDA for the HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System or Melphalan/HDS) seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM)
EUSA Pharma, a newly-established profitable specialty pharmaceutical business with global reach, had its official launch following the acquisition of five...
Medtronic plc has announced new clinical data from the NAVABLATE study, which highlights the much anticipated safety and performance results on microwave ablation used bronchoscopically with the Emprint Ablation Catheter Kit with Thermosphere Technology in conjunction with the Medtronic electromagnetic navigation bronchoscopy system.
Containing relevant Learning Zones, guidelines, trials and news.
In-depth learning materials and relevant resources by areas of interest for Healthcare Professionals.
Boston Scientific Corporation announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.